表紙
市場調査レポート

急性冠症候群:パイプライン製品の分析

Acute Coronary Syndrome - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232806
出版日 ページ情報 英文 114 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
急性冠症候群:パイプライン製品の分析 Acute Coronary Syndrome - Pipeline Review, H1 2016
出版日: 2016年05月11日 ページ情報: 英文 114 Pages
概要

急性冠症候群とは、急激な心臓への血流低下によって引き起こされるあらゆる状態を指し、胸あるいは左上腕部、あごなど身体の一部の痛み、悪心、嘔吐、呼吸困難などの症状があります。年齢や高血圧、高血中コレステロール、喫煙、2型糖尿病、などが素因であり、治療法には、ベータ遮断薬、カルシウム拮抗薬、コレステロール降下剤、ACE(アンジオテンシン変換酵素)阻害薬、ARB(アンジオテンシン受容体拮抗薬)などの投与があります。

当レポートでは、世界における急性冠症候群治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

  • 調査範囲

急性冠症候群の概要

治療薬の開発

  • パイプライン製品の概要

急性冠症候群:企業で開発中の治療薬

急性冠症候群:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

急性冠症候群:企業で開発中の製品

急性冠症候群の治療薬開発に従事している企業

  • advanceCor GmbH
  • Arena Pharmaceuticals, Inc.
  • Artery Therapeutics, Inc.
  • Athera Biotechnologies AB
  • Bayer AG
  • Cardiome Pharma Corp.
  • Cerenis Therapeutics Holding SA
  • CSL Limited
  • Esperion Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • 日本たばこ産業
  • Lee's Pharmaceutical Holdings Limited
  • MedImmune, LLC
  • Pfizer Inc.
  • The Medicines Company

急性冠症候群:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

急性冠症候群:最近のパイプライン動向

急性冠症候群:休止中のプロジェクト

急性冠症候群:開発が中止された製品

急性冠症候群:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8040IDB

Summary

Global Markets Direct's, 'Acute Coronary Syndrome - Pipeline Review, H1 2016', provides an overview of the Acute Coronary Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome
  • The report reviews pipeline therapeutics for Acute Coronary Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Coronary Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Acute Coronary Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Coronary Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Acute Coronary Syndrome - Overview
  • Acute Coronary Syndrome - Therapeutics under Development by Companies
  • Acute Coronary Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acute Coronary Syndrome - Products under Development by Companies
  • Acute Coronary Syndrome - Companies Involved in Therapeutics Development
    • advanceCor GmbH
    • Arena Pharmaceuticals, Inc.
    • Artery Therapeutics, Inc.
    • Athera Biotechnologies AB
    • Bayer AG
    • Cardiome Pharma Corp.
    • Cerenis Therapeutics Holding SA
    • CSL Limited
    • Esperion Therapeutics, Inc.
    • GlaxoSmithKline Plc
    • Japan Tobacco Inc.
    • Lee's Pharmaceutical Holdings Limited
    • MedImmune, LLC
    • Pfizer Inc.
    • The Medicines Company
  • Acute Coronary Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 4-WF - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEM-28 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEM-2802 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Artpep-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologics for Acute Coronary Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CER-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COR-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COR-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CSL-112 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dalcetrapib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • losmapimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MDCO-216 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MEDI-6012 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PC-mAb - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-06282999 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PMC-6 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PR-15 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rivaroxaban - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • temanogrel hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tirofiban hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZK-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acute Coronary Syndrome - Recent Pipeline Updates
  • Acute Coronary Syndrome - Dormant Projects
  • Acute Coronary Syndrome - Discontinued Products
  • Acute Coronary Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
      • Apr 25, 2016: Patent Term for Rivaroxaban Extended in US
      • Feb 23, 2016: Meta-Analysis of AGGRASTAT (Tirofiban HCl) Presented at CRT 2016 Conference
      • Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy
      • Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015
      • Oct 27, 2015: GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study)
      • Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients
      • Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides
      • Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery
      • May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Coronary Syndrome, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H1 2016
  • Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Acute Coronary Syndrome - Pipeline by Artery Therapeutics, Inc., H1 2016
  • Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H1 2016
  • Acute Coronary Syndrome - Pipeline by Bayer AG, H1 2016
  • Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H1 2016
  • Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H1 2016
  • Acute Coronary Syndrome - Pipeline by CSL Limited, H1 2016
  • Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H1 2016
  • Acute Coronary Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Acute Coronary Syndrome - Pipeline by Japan Tobacco Inc., H1 2016
  • Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016
  • Acute Coronary Syndrome - Pipeline by MedImmune, LLC, H1 2016
  • Acute Coronary Syndrome - Pipeline by Pfizer Inc., H1 2016
  • Acute Coronary Syndrome - Pipeline by The Medicines Company, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Acute Coronary Syndrome Therapeutics - Recent Pipeline Updates, H1 2016
  • Acute Coronary Syndrome - Dormant Projects, H1 2016
  • Acute Coronary Syndrome - Dormant Projects (Contd..1), H1 2016
  • Acute Coronary Syndrome - Discontinued Products, H1 2016
  • Acute Coronary Syndrome - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Acute Coronary Syndrome, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top